Latest articlesAll articles
Read on to learn how Methotrexate is fundamental to limiting progression in several rheumatic diseases such as rhe… twitter.com/i/web/status/1…
Posted 22 September
Circulating T Cell Clones in Preclinical Phases of Rheumatoid Arthritis ow.ly/6Ddd30pK8NN… twitter.com/i/web/status/1…
Posted 20 September
Subscribe to EMJ today to have the next EMJ #Rheumatology eJournal sent straight to you! ow.ly/w5XX30q3OFJ https://t.co/Hya4zIIBgF
Posted 19 September
We sit down with Meryvn Singer, Professor of Intensive Care Medicine, UCL, to discuss the role of intensive care in… twitter.com/i/web/status/1…
Posted 18 September
Latest abstractsAll abstracts
Differences in Low-Density Lipoprotein Particle Composition and Oxidation May Underlie the Paradoxical Association of Low Levels with Higher Coronary Atherosclerosis Burden in Rheumatoid Arthritis
In fact, patients with RA in the lowest low-density lipoprotein (LDL) group (<70 mg/dL) may experience an unexpectedly high CVD risk.2 The authors explored whether patients with LDL 130 mg/dL), as a reason for this risk.
Association Between Environmental Air Pollution and Rheumatoid Arthritis Flares
Environmental air pollution has been linked to the pathogenesis of rheumatoid arthritis (RA).1 Nevertheless, there is no evidence linking higher concentrations of air pollutants with the risk of RA reactivations.
RESOLVE-1, a Phase III Trial of Lenabasum for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Lenabasum is an oral, non-immunosuppressive, cannabinoid Type 2 receptor agonist that activates resolution of innate immune responses.1 In animal models of bleomycin-induced skin and lung fibrosis, lenabasum reduced inflammation and fibrosis